Clinical Translation of Targeted Protein Degraders
Clinical Pharmacology & Therapeutics · 2023-09 · 114 (3) · 558-568
DOI: 10.1002/cpt.2985 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 17.07.2023. Verfasst von Nikki R Kong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Proteins, Neoplasms. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 93 Literaturangaben.
Abstract (Originalsprache)
Targeted protein degradation (TPD) has emerged as a potentially transformational therapeutic modality with considerable promise. Molecular glue degraders remodel the surface of E3 ligases inducing interactions with neosubstrates resulting in their polyubiquitination and proteasomal degradation. Molecular glues are clinically precedented and have demonstrated the ability to degrade proteins‐of‐interest (POIs) previously deemed undruggable due to the absence of a traditional small molecule binding pocket. Heterobifunctional proteolysis targeting chimeras (PROTACs) possess ligands for an E3 complex and the POIs, which are chemically linked together, and similarly hijack the ubiquitin machinery to deplete the target. There has been a recent surge in the number of degraders entering clinical trials, particularly directed toward cancer. Nearly all utilize CRL4 CRBN as the E3 ligase, and a relatively limited diversity of POIs are currently targeted. In this review, we provide an overview of the degraders in clinical trials and provide a perspective on the lessons learned from their development and emerging human data that will be broadly useful to those working in the TPD field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Lyn H Jones
Zitieren
APA
Kong, N. R., & Jones, L. H. (2023). Clinical Translation of Targeted Protein Degraders. Clinical Pharmacology & Therapeutics, 114(3), 558-568. https://doi.org/10.1002/cpt.2985
Vancouver
Kong NR, Jones LH. Clinical Translation of Targeted Protein Degraders. Clinical Pharmacology & Therapeutics. 2023;114(3):558-568. doi:10.1002/cpt.2985
BibTeX
@article{Kong2023,
author = {Kong, Nikki R and Jones, Lyn H},
title = {Clinical Translation of Targeted Protein Degraders},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {114},
number = {3},
pages = {558--568},
doi = {10.1002/cpt.2985}
}
EUVIMED